Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01490723 · ClinicalTrials.gov registry record · Phase 2

Zevalin-Containing Nonmyeloablative Conditioning for Stem Cell Transplantation (SCT)

A Phase 2 study of Lymphoma and Leukemia, sponsored by M.D. Anderson Cancer Center.

Completed
Registry status
Phase 2
Development phase
20
Enrollment target
1
Study location

NCT01490723 is a Phase 2 study of Lymphoma and Leukemia that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 20 participants, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01490723, a Phase 2 study of Lymphoma and Leukemia, has completed, sponsored by M.D. Anderson Cancer Center.

COMPLETED
Registry status
Phase 2
Development phase
20 participants
Enrollment target
1
Study location

Study Summary

The goal of this clinical research study is to learn if adding Zevalin (ibritumomab tiuxetan) to low-intensity chemotherapy (the combination of rituximab, bendamustine, and fludarabine), followed by an allogeneic stem cell transplant, can help to control lymphoma. The safety of this combination will also be studied. Two (2) forms of ibritumomab tiuxetan will be used in this study. 90Y-ibritumomab tiuxetan is designed to attach to lymphoma cells and destroy the cells using a radioactive particle that is attached to it. 111In-ibritumomab tiuxetan is like 90Y- ibritumomab tiuxetan, but the radioactive particle that is attached to it does not kill lymphoma cells. The radioactive particle makes the drug able to be seen inside your body. It is being used in this study to predict how fast the study drug will travel in the body and how long the drug stays in the body. Rituximab is designed to attach to lymphoma cells, which may cause them to die. Bendamustine is designed to damage and destroy the DNA (genetic material) of cancer cells. Fludarabine is designed to make cancer cells less able to repair damaged DNA. This may increase the likelihood of the cells dying.

Conditions Studied

Lymphoma Leukemia

Interventions

  • DRUG Fludarabine
  • DRUG Rituximab
  • DRUG 111In Ibritumomab
  • PROCEDURE Planar Scintigraphy Imaging
  • DRUG 90Y IbritumomabTiuxetan

Study Locations (1)

Texas

  • University of Texas MD Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2013-01
Est. Completion 2019-04-24
Phase Phase 2

Sponsor

M.D. Anderson Cancer Center

2,692 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01490723

The ClinicalTrials.gov registry entry for NCT01490723 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (96% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Lymphoma appearing as the primary indexed condition, and to 5 interventions - of which Fludarabine is the first listed.

NCT01490723 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT01490723 about?

NCT01490723 is a clinical study titled "Zevalin-Containing Nonmyeloablative Conditioning for Stem Cell Transplantation (SCT)". The goal of this clinical research study is to learn if adding Zevalin (ibritumomab tiuxetan) to low-intensity chemotherapy (the combination of rituximab, bendamustine, and fludarabine), followed by an allogeneic stem cell transplant, can help to control lymphoma. The safety of this combination will...

What is the current status of trial NCT01490723?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2013-01. Estimated completion is 2019-04-24.

What conditions does trial NCT01490723 study?

This clinical trial studies the following conditions: Lymphoma, Leukemia.

What interventions are being tested in trial NCT01490723?

The interventions under investigation include: Fludarabine (DRUG), Rituximab (DRUG), 111In Ibritumomab (DRUG), Planar Scintigraphy Imaging (PROCEDURE), 90Y IbritumomabTiuxetan (DRUG).

Who is sponsoring clinical trial NCT01490723?

This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01490723 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Lymphoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Lymphoma

All registered trials for this condition

Leukemia

All registered trials for this condition

Texas

All trials with a study site in Texas

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.